Multi-specific immune targeting molecules and uses thereof
AssigneeJanssen Biotech, Inc.
InventorsRajkumar GANESAN, Michael Riis HANSEN, Iqbal S. GREWAL, Sanjaya SINGH
Life of this patent
Estimating the term…
Abstract
Provided herein are trispecific antibodies or antigen binding fragments thereof that bind to Vβ17, CD28 and another target (e.g., a cancer antigen, such as BCMA or PSMA) are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
Claims33
A trispecific antibody comprising:
- (a) a first binding domain that binds to Vβ17, (b) a second binding domain that binds to cancer antigen, and (c) a third binding domain that binds to CD28;
- wherein optionally the cancer antigen is BCMA, or
- wherein optionally the cancer antigen is PSMA.
-13. (canceled)
(canceled)
(canceled)
-42. (canceled)
A trispecific antibody comprising:
- a first means capable of binding Vβ17 on the surface of a T cell;
- a second means capable of binding a cancer antigen on the surface of a cancer cell;
- and a third means capable of binding CD28 on the surface of the T cell;
- wherein optionally, the cancer antigen is BCMA and the cancer cell is a B cell cancer cell, or
- wherein optionally, the cancer antigen is PSMA and the cancer cell is a prostate cancer cell.
(canceled)
(canceled)
A process for making an antibody that binds to more than one target molecule, the process comprising:
- a step for performing a function of obtaining a first binding domain capable of binding to Vβ17 on a T cell;
- a step for performing a function of obtaining a second binding domain capable of binding to cancer antigen on a cancer cell;
- a step for performing a function of obtaining a third binding domain capable of binding to CD28 on a T cell;
- and a step for performing a function of providing an antibody capable of binding to a Vβ17 antigen on the T cell, a cancer antigen on the cancer cell and the CD28 antigen on the T cell;
- wherein (i) the step for performing a function of obtaining a second binding domain that binds to the cancer antigen on the cancer cell is repeated n times, and further comprising n steps for performing a function of providing a first binding domain that binds to Vβ17 present on a T cell and n number of target molecules, wherein n is at least 2, or (ii) the step for performing a function of obtaining a third binding domain that binds to the CD28 on the T cell is repeated n times, and further comprising n steps for performing a function of providing a first binding domain that binds to Vβ17 present on a T cell and n number of target molecules, wherein n is at least 2.
(canceled)
-65. (canceled)
(canceled)
-75. (canceled)
Dependencies are inferred from the claim text.